Detalles de la búsqueda
1.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Am Heart J
; 274: 32-45, 2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705341
2.
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10289): 2060-2069, 2021 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34015342
3.
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Lipids Health Dis
; 14: 98, 2015 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26328624
4.
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib.
J Clin Pharmacol
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38720593
5.
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial.
J Atheroscler Thromb
; 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38569868
6.
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
J Clin Lipidol
; 17(4): 491-503, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37277261
7.
Novel developments in omega-3 fatty acid-based strategies.
Curr Opin Lipidol
; 22(6): 437-44, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21986642
8.
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
Nat Med
; 28(8): 1672-1678, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953719
9.
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD.
Kidney360
; 2(2): 224-235, 2021 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35373026
10.
Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Clin Ther
; 27(4): 472-83, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15922820
11.
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Expert Rev Cardiovasc Ther
; 12(9): 1045-54, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25089906
12.
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
J Clin Lipidol
; 8(1): 94-106, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24528690
13.
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Vasc Health Risk Manag
; 9: 563-73, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24124374
14.
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Clin Ther
; 35(9): 1400-11.e1-3, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23998969
15.
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
J Clin Lipidol
; 6(6): 573-84, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23312053
Resultados
1 -
15
de 15
1
Próxima >
>>